Pioneering solutions, saving lives
Research is critical to combatting brain disease and improving the lives of those impacted, today and in the future.
Conducted by The Royal Melbourne Hospital’s Departments of Neurology and Neurosurgery, the active research programs and clinical trials supported by the Foundation cover an extensive breadth of neurological conditions.
Patients wishing to participate are encouraged to view the relevant trial and contact the trial co-ordinator for more information.
| Brain Tumour / Neurosurgery: | NsurgClerk@mh.org.au |
| Dementia: | DementiaTrials@mh.org.au |
| Epilepsy: | EpilepsyCoordinator@mh.org.au |
| Huntington’s Disease: | RMHHuntingtonDiseaseStudies@mh.org.au |
| Movement Disorders: | MovementDisorders@mh.org.au |
| Multiple Sclerosis: | MSClinic@mh.org.au |
| Neurophysiology: | RMH-ClinicalNeurophysiology@mh.org.au |
| Stroke: | RMH-StrokeResearchTeam@mh.org.au |
| General: | Neuro.Foundation@mh.org.au |
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures (XTOLE3)
PERsonalised Selection Of medication for Newly diagnosed Adult epiLepsy - the PERSONAL Trial
A Phase 2/3 Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety, and Tolerability of BHV-7000 as Adjunctive Therapy in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic
A Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy